TY - JOUR
T1 - Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension
AU - Bersohn, Malcolm M.
AU - Turner, Michelle P.
AU - Traiger, Glenna L.
AU - Frost, Adaani E.
AU - Shapiro, Shelley
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Bersohn has received grant/research support from Actelion Pharmaceuticals US Inc, Bayer, Biotronik SE & CoKG, Medtronic Inc, and St. Jude Medical Inc. Ms Turner is employed by ICON Late Phase & Outcomes Research, a company that receives research support from Actelion Pharmaceuticals US Inc on behalf of Cotherix Inc and other pharmaceutical companies. Ms Traiger serves as a consultant and is on the speakers' bureau for Actelion Pharmaceuticals US Inc, United Therapeutics Corp, and Gilead Sciences Inc. Dr Frost serves as a consultant for Actelion Pharmaceuticals US Inc, and Gilead Sciences Inc; has received honoraria from Actelion Pharmaceuticals US Inc, Gilead Sciences Inc, and Pfizer Inc; has provided expert testimony on diet-pill litigation; has received (through Baylor University) funds for institutional review board-approved research from Gilead Sciences Inc, Actelion Pharmaceuticals US Inc, United Therapeutics Corp, Eli Lilly and Company, Pfizer Inc, Novartis Pharmaceuticals Corp., and Bayer Pharmaceuticals Corp.; and has received honoraria for her service on the REVEAL Registry Steering Committee, which is supported by Actelion Pharmaceuticals US Inc on behalf of Cotherix Inc. Dr Shapiro has received research grants from Actelion Pharmaceuticals US Inc, Pfizer Inc, Gilead Sciences Inc, United Therapeutics Corp, Medtronic Inc, GeNO LLC, and Bayer Pharmaceuticals, Inc; has served as a consultant for Gilead Sciences Inc and United Therapeutics Corp; and has served as a speaker for Actelion Pharmaceuticals US Inc, United Therapeutics Corp, and Gilead Sciences Inc.
Funding Information:
Other contributions: Medical writing support was provided by Latoya M. Mitchell, PhD, and Kathryn Leonard, of inScience Communications, Springer Healthcare. SAS programming support was provided by Ginny Lai of ICON Late Phase & Outcomes Research (ICON plc) and funding was provided by Actelion Pharmaceuticals US, Inc. We thank the principal investigators and their study coordinators for their participation in the REVEAL Registry (available in e-Appendix 1).
PY - 2013/9
Y1 - 2013/9
N2 - Background: Heart rate (HR) and systolic BP (SBP) are signifi cant multivariate predictors of survival in patients with pulmonary arterial hypertension (PAH) as part of a 19-element formula. To what extent HR and BP alone predict survival and future hospitalization in patients with PAH is unknown. Methods: We analyzed data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry), a prospective, observational study of patients with PAH. Patients were analyzed by quintile (Q) according to values of HR, SBP, and SBP/HR. Kaplan-Meier curves were calculated by Q for survival and freedom from hospitalization. Results: For patients in the worst Q, 1-year survival after enrollment was 85% ± 2% for SBP, 86% ± 2% for HR, and 84% ± 2% for SBP/HR vs 91% ± 1% for the middle three Qs (P <.001). Hospitalization occurred more frequently than mortality but with a similar pattern among Qs. One-year survival after fi rst follow-up of patients in the worst Q for change (Δ) in SBP since enrollment was 85% ± 2% (P =.004), 86% ± 2% for Δ HR (P =.12), and 84% ± 2% for ± SBP/HR (P =.024) vs the middle three Qs (Δ SBP: 91% ± 1%; Δ HR: 90% ± 1%; Δ SBP/HR: 90% ± 1%). Conclusions: Changes in vital signs from enrollment to fi rst follow-up were less predictive of mortality than the values of vital-sign parameters at either enrollment or fi rst follow-up. HR, SBP, and SBP/HR at enrollment identifi ed high-risk groups with survival differences of 5% to 7% and freedom from hospitalization differences of 9% to 11% vs lower-risk groups. SBP/HR defi nes the highest-risk group, including most of the high-risk patients defi ned by HR and SBP separately.
AB - Background: Heart rate (HR) and systolic BP (SBP) are signifi cant multivariate predictors of survival in patients with pulmonary arterial hypertension (PAH) as part of a 19-element formula. To what extent HR and BP alone predict survival and future hospitalization in patients with PAH is unknown. Methods: We analyzed data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry), a prospective, observational study of patients with PAH. Patients were analyzed by quintile (Q) according to values of HR, SBP, and SBP/HR. Kaplan-Meier curves were calculated by Q for survival and freedom from hospitalization. Results: For patients in the worst Q, 1-year survival after enrollment was 85% ± 2% for SBP, 86% ± 2% for HR, and 84% ± 2% for SBP/HR vs 91% ± 1% for the middle three Qs (P <.001). Hospitalization occurred more frequently than mortality but with a similar pattern among Qs. One-year survival after fi rst follow-up of patients in the worst Q for change (Δ) in SBP since enrollment was 85% ± 2% (P =.004), 86% ± 2% for Δ HR (P =.12), and 84% ± 2% for ± SBP/HR (P =.024) vs the middle three Qs (Δ SBP: 91% ± 1%; Δ HR: 90% ± 1%; Δ SBP/HR: 90% ± 1%). Conclusions: Changes in vital signs from enrollment to fi rst follow-up were less predictive of mortality than the values of vital-sign parameters at either enrollment or fi rst follow-up. HR, SBP, and SBP/HR at enrollment identifi ed high-risk groups with survival differences of 5% to 7% and freedom from hospitalization differences of 9% to 11% vs lower-risk groups. SBP/HR defi nes the highest-risk group, including most of the high-risk patients defi ned by HR and SBP separately.
UR - http://www.scopus.com/inward/record.url?scp=84884341881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884341881&partnerID=8YFLogxK
U2 - 10.1378/chest.12-2572
DO - 10.1378/chest.12-2572
M3 - Article
C2 - 23598723
AN - SCOPUS:84884341881
SN - 0012-3692
VL - 144
SP - 959
EP - 965
JO - CHEST
JF - CHEST
IS - 3
ER -